# An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)

> **NCT05483322** · — · NO_LONGER_AVAILABLE · sponsor: **OrphAI Therapeutics**

## Conditions studied

- Frontotemporal Dementia

## Interventions

- **DRUG:** LAM-002A

## Key facts

- **NCT ID:** NCT05483322
- **Lead sponsor:** OrphAI Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05483322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05483322, "An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05483322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*